Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Burkitt Lymphoma 12Prostatic Neoplasms 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Plasmablastic Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Immunoblastic Lymphadenopathy 2Enteropathy-Associated T-Cell Lymphoma 2Neuroblastoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Primary Effusion 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Hormone-Resistant Prostate Cancer 1Hodgkin Disease 1Hematologic Neoplasms 1HIV Infections 1Composite Lymphoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Blast Crisis 1

Interventions

prednylidene 1deltacortene 1cabazitaxel 1XRP6258 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hormone-Resistant Prostate Cancer × prednylidene × Clear all
NCT02844582 2021-01-25

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

Phase 2 Terminated
2 enrolled 5 charts
Genitourinary

Hormone-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡